New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications

Cited by (561)

Items 201–300 of 561

1. A one-step real-time RT-PCR assay for simultaneous typing of SARS-CoV-2 mutations associated with the E484K and N501Y spike protein amino-acid substitutions
   Serafeim C. Chaintoutis, Taxiarchis Chassalevris, George Tsiolas, Sofia Balaska, Ioannis Vlatakis, Evangelia Mouchtaropoulou, Victoria I. Siarkou, Areti Tychala, Dimitris Koutsioulis, Lemonia Skoura et al. · 2021 · Journal of Virological Methods
2. Site Specific N- and O-glycosylation mapping of the Spike Proteins of SARS-CoV-2 Variants of Concern
   A. Shajahan, Lauren E. Pepi, Bhoj Kumar · 2022 · Research Square
3. A sigh of relief: vaccine-associated hypermetabolic lymphadenopathy following the third COVID-19 vaccine dose is short in duration and uncommonly interferes with the interpretation of [18F]FDG PET-CT studies performed in oncologic patients
   Dan Cohen, Shir Hazut Krauthammer, Ido Wolf, Einat Even‐Sapir · 2021 · European Journal of Nuclear Medicine and Molecular Imaging
4. Roles of generation-interval distributions in shaping relative epidemic strength, speed, and control of new SARS-CoV-2 variants
   Sang Woo Park, B. M. Bolker, S. Funk · 2021 · medRxiv
5. Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19
   Qi Liu, Sensen Chi, Kostyantyn V. Dmytruk, Olena V. Dmytruk, Shuai Tan · 2022 · Viruses
6. COVseq is a cost-effective workflow for mass-scale SARS-CoV-2 genomic surveillance
   Michele Simonetti, Ning Zhang, Luuk Harbers, Maria Grazia Milia, Silvia Brossa, Thi Thu Huong Nguyen, Francesco Cerutti, Enrico Berrino, Anna Sapino, Magda Bienko et al. · 2021 · Nature Communications
7. Modelling SARS-CoV-2 Binding Antibody Waning 8 Months after BNT162b2 Vaccination
   Angelos E. Hatzakis, Andreas Karabinis, Sotirios Roussos, Nikos Pantazis, Dimitrios Degiannis, Antigoni S. Chaidaroglou, Konstantinos Th. Petsios, Ioanna D. Pavlopoulou, Sotirios Tsiodras, Dimitrios N. Paraskevis et al. · 2022 · Vaccines
8. Competent immune responses to SARS-CoV-2 variants in older adults following two doses of mRNA vaccination
   Mladen Jergović, Jennifer L. Uhrlaub, Makiko Watanabe, Christine M. Bradshaw, Lisa M. White, Bonnie LaFleur, Taylor Edwards, Ryan S. Sprissler, Michael Worobey, Deepta Bhattacharya et al. · 2022 · Nature Communications
9. A reasoned approach towards administering COVID‐19 vaccines to pregnant women
   Angsumita Pramanick, Abhiram Kanneganti, Jing Lin Jeslyn Wong, Sarah Weiling Li, Pooja Sharma Dimri, Aniza Puteri Mahyuddin, Sailesh Kumar, Sebastian Enrique Illanes, Jerry Kok Yen Chan, Lin Su et al. · 2021 · Prenatal Diagnosis
10. Local emergence and decline of a SARS-CoV-2 variant with mutations L452R and N501Y in the spike protein
    Jan‐Philipp Mallm, Christian Bundschuh, Heeyoung Kim, Niklas Weidner, Simon Steiger, Isabelle Lander, Kathleen Börner, Katharina Bauer, Daniel Hübschmann, Vladimı́r Beneš et al. · 2021 · medRxiv
11. Alternatives to animal models and their application in the discovery of species susceptibility to SARS-CoV-2 and other respiratory infectious pathogens: A review
    Sandra Runft, Iris Färber, Johannes Krüger, Nadine Krüger, Federico Armando, Cheila Rocha, Stefan Pöhlmann, Laura Burigk, Eva Leitzen, Małgorzata Ciurkiewicz et al. · 2022 · Veterinary Pathology
12. Cocktail of REGN Antibodies Binds More Strongly to SARS-CoV-2 Than Its Components, but the Omicron Variant Reduces Its Neutralizing Ability
    Hung Van Nguyen, Pham Dang Lan, Daniel Allen Nissley, Edward P. O’Brien, Mai Suan Li · 2022 · The Journal of Physical Chemistry B
13. Controlling long-term SARS-CoV-2 infections can slow viral evolution and reduce the risk of treatment failure
    Debra Van Egeren, Alexander Novokhodko, Madison Stoddard, Uyen Tran, Bruce R. Zetter, Michael S. Rogers, Diane Joseph‐McCarthy, Arijit Chakravarty · 2021 · Scientific Reports
14. Therapeutic potential of salicylamide derivatives for combating viral infections
    Jimin Xu, Yu Xue, Andrew A. Bolinger, Jun Li, Mingxiang Zhou, Haiying Chen, Hongmin Li, Jia Zhou · 2023 · Medicinal Research Reviews
15. Projecting the impact of Covid-19 variants and vaccination strategies in disease transmission using a multilayer network model in Costa Rica
    Yury E. García, Gustavo Mery, Paola Vásquez, Juan G. Calvo, Luis A. Barboza, Tania Rivas, Fabio Sánchez · 2022 · Scientific Reports
16. Lessons from two SARS-CoV-2 waves in South Africa
    L. Bekker, N. Ntusi · 2021 · Lancet Global Health
17. Genomic epidemiology of SARS-CoV-2 in Mauritius reveals a new wave of infections dominated by the B.1.1.318, a variant under investigation
    Houriiyah Tegally, Magalutcheemee Ramuth, Daniel Amoaka, Cathrine Scheepers, Eduan Wilkinson, Marta Giovanetti, Richard J. Lessells, Jennifer Giandhari, Arshad Ismail, Darren Patrick Martin et al. · 2021 · medRxiv
18. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach
    Yash Gupta, Sumit Kumar, Samantha E. Zak et al. · 2021 · Bioorganic & Medicinal Chemistry
19. Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease‐19 pandemic
    Jatin Chadha, Lavanya Khullar, Nidhi Mittal · 2021 · Environmental Microbiology
20. Humoral and cellular immune response against SARS-CoV-2 variants following heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
    2021
21. Widespread contamination of SARS‐CoV ‐2 on highly touched surfaces in Brazil during the second wave of the COVID ‐19 pandemic
    Severino Jefferson Ribeiro da Silva, Jéssica Catarine Frutuoso do Nascimento, Wendell Palôma Maria dos Santos Reis, Caroline Targino Alves da Silva, Poliana Gomes da Silva, Renata Pessôa Germano Mendes, Allyson Andrade Mendonça, Bárbara Nazly Rodrigues Santos, Jurandy Júnior Ferraz de Magalhães, Alain Kohl et al. · 2021 · Environmental Microbiology
22. Efficient CRISPR-Cas13d-Based Antiviral Strategy to Combat SARS-CoV-2
    Mouraya Hussein, Zaria Andrade Dos Ramos, Monique A. Vink · 2023 · Viruses
23. Needle‐free injection system delivery of ZyCoV‐D DNA vaccine demonstrated improved immunogenicity and protective efficacy in rhesus macaques against SARS‐CoV‐2
    P. Yadav, Sanjay Kumar, K. Agarwal, M. Jain, Dilip R Patil, Kapil Maithal, B. Mathapati, S. Giri, S. Mohandas, A. Shete et al. · 2023 · Journal of Medical Virology
24. Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19
    Hong Zhou, Wei‐Jian Ni, Wei Huang, Zhen Wang, Ming Cai, Yan-Cai Sun · 2022 · Frontiers in Immunology
25. The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
    Ahmed Zaqout, Joanne Daghfal, Israa Alaqad, Saleh A.N. Hussein, Abdullah Aldushain, Muna A. Rahman S. AlMaslamani, Mohammed Abukhattab, Ali Senosi Omrani · 2021 · International Journal of Infectious Diseases
26. Optimizing testing regimes for the detection of COVID-19 in children and older adults
    Nidhi Chauhan, Shringika Soni, Utkarsh Jain · 2021 · Expert Review of Molecular Diagnostics
27. Inactivation of SARS-CoV-2 by deep ultraviolet light emitting diode: A review
    Takeo Minamikawa, Takaaki Koma, Akihiro Suzuki, Kentaro Nagamatsu, Takeshi Yasui, Koji Yasutomo, Masako Nomaguchi · 2021 · Japanese Journal of Applied Physics
28. Receptor binding domain proteins of SARS‐CoV‐2 variants produced in Nicotiana benthamiana elicit neutralizing antibodies against variants of concern
    Narach Khorattanakulchai, Suwimon Manopwisedjaroen, Kaewta Rattanapisit, Chalisa Panapitakkul, Taratorn Kemthong, Nutchanat Suttisan, Kanjana Srisutthisamphan, Suchinda Malaivijitnond, Arunee Thitithanyanont, Anan Jongkaewwattana et al. · 2022 · Journal of Medical Virology
29. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries
    Asim Hussain, Hamza Rafeeq, Hafiza Memoona Asif, Sumaira Shabbir, Muhammad Bilal, Sikandar Imamsab Mulla, Marcelo Franco, Hafiz M.N. Iqbal · 2021 · International Immunopharmacology
30. Antibody cocktail effective against variants of SARS-CoV-2
    Kang-Hao Liang, Pao-Yin Chiang, Shih-Han Ko, Yu‐Chi Chou, Ruei‐Min Lu, Hsiu-Ting Lin, Chen Wy, Yi‐Ling Lin, Mi‐Hua Tao, Jia‐Tsrong Jan et al. · 2021 · Journal of Biomedical Science
31. Real-Time Genomic Surveillance for SARS-CoV-2 Variants of Concern, Uruguay
    Natalia Rego, Alicia Costábile, Mercedes Paz, Cecilia Salazar, Paula Perbolianachis, Lucía Spangenberg, Ignacio Ferrés, Rodrigo Arce, Álvaro Fajardo, Mailén Arleo et al. · 2021 · Emerging infectious diseases
32. Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: implications for the ability of serological assays to predict immunity
    Frauke Muecksch, H. Wise, K. Templeton, Becky Batchelor, M. Squires, Kirsty McCance, L. Jarvis, K. Malloy, E. Furrie, C. Richardson et al. · 2021 · medRxiv
33. Adjuvant-Protein Conjugate Vaccine with Built-In TLR7 Agonist on S1 Induces Potent Immunity against SARS-CoV-2 and Variants of Concern
    Ruyan Zhang, Shihao Zhou, Chen-Bin He, Jian Wang, Yu Wen, Ran-Ran Feng, Xuguang Yin, Guang‐Fu Yang, Jun Guo · 2022 · ACS Infectious Diseases
34. Clinical severity of COVID-19 patients admitted to hospitals during the Omicron wave in South Africa
    W. Jassat, S. A. Karim, C. Mudara et al. · 2022 · medRxiv
35. Application of omics technology to combat the COVID‐19 pandemic
    Jingjing Yang, Yunzheng Yan, Wu Zhong · 2021 · MedComm
36. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike
    Ying Fu, Juliana da Fonseca Rezende e Mello, Bryan D. Fleming et al. · 2022 · PLoS ONE
37. Anti-SARS-CoV-2 equine F (Ab′)2 immunoglobulin as a possible therapy for COVID-19
    V. Botosso, S. Jorge, R. Astray, A. M. de Sá Guimarães, M. Mathor, de Carneiro Patrícia dos Santos, E. Durigon, D. Covas, D. B. D. de Oliveira, Ricardo das Neves Oliveira et al. · 2022 · Scientific Reports
38. Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities
    Shelan Liu, Min Kang, Na Zhao, Yali Zhuang, Shijian Li, Tie Song · 2022 · Medical Review
39. Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial
    Meagan P. O'Brien, Eduardo Forleo-Neto, N. Sarkar et al. · 2021 · medRxiv
40. Mannose-specific plant and microbial lectins as antiviral agents: A review
    Ankita Gupta, Kusum Yadav, Anurag Yadav, Rumana Ahmad, Aditi Srivastava, Dileep Kumar, Mohammad Amir Khan, Upendra Nath Dwivedi · 2024 · Glycoconjugate Journal
41. Nanotechnology-based approaches in the fight against SARS-CoV-2
    Alrayan Abass Albaz, Misbahuddin M. Rafeeq, Ziaullah Mirza Sain, Wael Abdullah Almutairi, Ali Saeed Alamri, Ahmed Hamdan Aloufi, Waleed Hassan Almalki, Mohammed Tarique · 2021 · AIMS Microbiology
42. Biparatopic nanobodies targeting the receptor binding domain efficiently neutralize SARS-CoV-2
    Phillip Pymm, Samuel J. Redmond, Olan Dolezal, Francesca L. Mordant, Ester López, James P. Cooney, Kathryn C. Davidson, Ebene R. Haycroft, Chee Wah Tan, Rebecca Seneviratna et al. · 2022 · iScience
43. How unequal vaccine distribution promotes the evolution of vaccine escape
    Philip J. Gerrish, Fernando Saldaña, Benjamin Galeota-Sprung, Alexandre Colato, Erika Elizabeth Rodríguez‐Torres, Jorge X. Velasco‐Hernández · 2021 · medRxiv
44. A safe haven of SARS-CoV-2 in the environment: Prevalence and potential transmission risks in the effluent, sludge, and biosolids
    Bashir Adelodun, Pankaj Kumar, Golden Odey, Fidelis Odedishemi Ajibade, Rahmat Gbemisola Ibrahim, Saad Alamri, Sulaiman Abdullah Alrumman, Ebrahem M. Eid, Vinod Kumar, Khalid Adeola Adeyemi et al. · 2022 · Geoscience Frontiers
45. Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency
    Sabrina Mariotti, Antonio Capocefalo, Maria Vincenza Chiantore, Angelo Iacobino, Raffaela Teloni, Maria Laura De Angelis, Alessandra Gallinaro, Maria Franca Pirillo, Martina Borghi, Andrea Canitano et al. · 2021 · Frontiers in Immunology
46. Vaccination games in prevention of infectious diseases with application to COVID-19
    Jing-Wen Ge, Wen-Di Wang · 2022 · Chaos, Solitons & Fractals
47. Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2’s pathogenicity factors
    Ömür Baysal, Naeem Abdul Ghafoor, Ragıp Soner Silme, Alexander N. Ignatov, Volha Kniazeva · 2021 · PLoS ONE
48. Effects of Casirivimab/Imdevimab Monoclonal Antibody Treatment among Vaccinated Patients Infected by SARS-CoV-2 Delta Variant
    G. Cicchitto, Lorena Cardillo, C. de Martinis et al. · 2022 · Viruses
49. The Dominance of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 and Its Sublineages and Associations with Mortality during the COVID-19 Pandemic in India between 2020 and 2021
    Bakilapadavu Venkatraja, Srilakshminarayana Gali, Ballamoole Krishna Kumar · 2021 · American Journal of Tropical Medicine and Hygiene
50. Transmissibility and pathogenicity of SARS-CoV-2 variants in animal models
    Young-Il Kim, Mark Anthony B. Casel, Young-Ki Choi · 2022 · Journal of Microbiology
51. Immune responses and reactogenicity after ChAdOx1 in individuals with past SARS-CoV-2 infection and those without
    So-Yun Lim, Ji Yeun Kim, Jin-Ah Lee et al. · 2021 · Journal of Infection
52. Surviving the Storm: Cytokine Biosignature in SARS-CoV-2 Severity Prediction
    Rahnuma Ahmad, Mainul Haque · 2022 · Vaccines
53. Association between prognostic factors and the outcomes of patients infected with SARS-CoV-2 harboring multiple spike protein mutations
    Gunadi Gunadi, Mohamad Saifudin Hakim, Hendra Wibawa, Marcellus, Ika Trisnawati, Endah Supriyati, Afiahayati, Riat El Khair, Kristy Iskandar, Siswanto Siswanto et al. · 2021 · Scientific Reports
54. Structure-guided design of direct-acting antivirals that exploit the gem-dimethyl effect and potently inhibit 3CL proteases of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) and middle east respiratory syndrome coronavirus (MERS-CoV)
    Chamandi S. Dampalla, Matthew J. Miller, Yunjeong Kim, Alexandria Zabiegala, Harry Nhat Nguyen, Trent K Madden, Hayden A. Thurman, Alexandra J. Machen, A. Cooper, Li-Jun Liu et al. · 2023 · European journal of medicinal chemistry
55. Forecasting local hospital bed demand for COVID-19 using on-request simulations
    Raisa Kociurzynski, Angelo D’Ambrosio, Alexis Papathanassopoulos, Fabian Bürkin, Stephan Hertweck, Vanessa M. Eichel, Alexandra Heininger, Jan Liese, Nico T. Mutters, Silke Peter et al. · 2023 · Scientific Reports
56. Nanoparticles for Coronavirus Control
    Maryam Kianpour, Mohsen Akbarian, Vladimir Nikolaevich Uversky · 2022 · Nanomaterials
57. Monitoring SARS-CoV-2 variants in wastewater of Dhaka City, Bangladesh: approach to complement public health surveillance systems
    Rehnuma Haque, M. E. Hossain, M. Miah · 2023 · Human Genomics
58. SARS-COV-2/COVID-19: scenario, epidemiology, adaptive mutations, and environmental factors
    Asma Asghar, Hafiz Muhammad Imran, Naheed Bano, Sadia Maalik, Sajida Mushtaq, Asim Hussain, Sunita Varjani, Lotfi Aleya, Hafiz M.N. Iqbal, Muhammad Bilal · 2022 · Environmental Science and Pollution Research
59. Reduced amplification efficiency of the RNA-dependent-RNA-polymerase target enables tracking of the Delta SARS-CoV-2 variant using routine diagnostic tests
    Ziyaad Valley‐Omar, Gert J.K. Marais, Arash Iranzadeh, Michelle Naidoo, Stephen N.J. Korsman, Tongai Gibson Maponga, Hannah Sophia Hussey, Mary‐Ann Davies, Andrew Boulle, Deelan Doolabh et al. · 2022 · Journal of Virological Methods
60. Genomic assessment of quarantine measures to prevent SARS-CoV-2 importation and transmission
    Dinesh Aggarwal, Andrew J. Page, Ulf Schaefer, George M. Savva, Richard E. Myers, Erik Volz, Nicholas A.F. Ellaby, Steven Platt, Natalie Groves, Eileen Gallagher et al. · 2022 · Nature Communications
61. Estimation of COVID-19 Period Prevalence and the Undiagnosed Population in Canadian Provinces: Model-Based Analysis
    Abdullah Hamadeh, Zeny Z. Feng, Jessmyn Niergarth, William W. L. Wong · 2021 · JMIR Public Health and Surveillance
62. Survey of Adherence with COVID-19 Prevention Behaviors During the 2020 Thanksgiving and Winter Holidays Among Members of the COVID-19 Community Research Partnership
    J. Peacock, D. Herrington, S. Edelstein et al. · 2021 · Journal of community health
63. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
    Simone Pecetta, Sven Kratochvil, Yu Kato, Kumaran Vadivelu, Rino Rappuoli · 2022 · Pharmacological Reviews
64. Revelation of Potent Epitopes Present in Unannotated ORF Antigens of SARS-CoV-2 for Epitope-Based Polyvalent Vaccine Design Using Immunoinformatics Approach
    Patil Pranita Uttamrao, Chakkarai Sathyaseelan, L. Ponoop Prasad Patro, Thenmalarchelvi Rathinavelan · 2021 · Frontiers in Immunology
65. Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies
    Carolina Corrêa Giron, Aatto Laaksonen, Fernando Luís Barroso da Silva · 2022 · Journal of Biomolecular Structure and Dynamics
66. An Antigenic Space Framework for Understanding Antibody Escape of SARS-CoV-2 Variants
    Nathaniel L. Miller, Thomas Clark, Rahul Raman, Ram Sasisekharan · 2021 · Viruses
67. How to End the COVID-19 Pandemic by March 2022
    Ruchir Agarwal, T. Reed · 2021 · Policy Research Working Papers
68. Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice
    Gabriela Chávez‐Calvillo, Whitney Burns, Liliana Garcia, Gerelyn Henry, Anthony Biancofiori, Albert George, Ciera Duffy, Justin Chu, Morgan Sides, Melissa Muñoz et al. · 2022 · Viruses
69. A bibliometric analysis of inflammatory bowel disease and COVID-19 researches
    Fangfei Wang, Jinliang Xie, Huifang Xiong, Yongke Xie · 2023 · Frontiers in Public Health
70. Targeting intracellular Neu1 for coronavirus infection treatment
    Darong Yang, Yin Wu, Isaac M. Turan, Joseph M. Keil, Kui Li, Michael H. Chen, Runhua Liu, Lizhong Wang, Xue‐Long Sun, Guo‐Yun Chen · 2023 · iScience
71. Live Virus Neutralisation of the 501Y.V1 and 501Y.V2 SARS-CoV-2 Variants following INO-4800 Vaccination of Ferrets
    Shane Riddell, Sarah Goldie, Alexander J. McAuley, Michael J. Kuiper, Peter A. Durr, Kim R. Blasdell, Mary Tachedjian, Julian D Druce, Trevor R.F. Smith, Kate E. Broderick et al. · 2021 · Frontiers in Immunology
72. Detecting SARS-CoV-2 Orf3a and E ion channel activity in COVID-19 blood samples
    Han‐Gang Yu, Gina Sizemore, Katy Smoot, Peter L. Perrotta · 2021 · Journal of Clinical and Translational Science
73. The changing health impact of vaccines in the COVID-19 pandemic: A modeling study
    Jamie A. Cohen, Robyn M. Stuart, Jasmina Panovska‐Griffiths, Edinah Mudimu, Romesh Abeysuriya, Cliff C. Kerr, Michael Famulare, Daniel J. Klein · 2023 · Cell Reports
74. Analytical and clinical performances of a SARS-CoV-2 S-RBD IgG assay: comparison with neutralization titers
    2021
75. Immune response variables and viral mutations impact on COVID-19 reinfection and relapse
    Sarvin Sanaie, Elham Golipour, Ali Shamekh, Mohammad Reza Sadaie, Ata Mahmoodpoor, Mehdi Yousefi · 2021 · International Immunopharmacology
76. Mortality in hospitalized older adults with COVID‐19 during three waves: A multicenter retrospective cohort study
    Eric Kai Chung Wong, Jennifer Ann Watt, Hanyan Zou, Arthana Chandraraj, Alissa W. Zhang, Richard Norman, Katrina Lynn Piggott, Sharon Elizabeth Straus, Barbara Liu · 2022 · Health Science Reports
77. COVID-19, corticosteroids and public health: a reappraisal
    M. Fernandes, Jan Brábek · 2021 · Public Health
78. Variantes de SARS-CoV-2, una historia todavía inacabada
    Marta Pérez-Abeledo, J.C. Sanz Moreno · 2021 · Vacunas
79. COVID-19 Risk Assessment for the Tokyo Olympic Games
    Wenhui Zhu, Jie Feng, Cheng Li, Huimin Wang, Yang Zhong, Lijun Jane Zhou, Xingyu Zhang, Tao Zhang · 2021 · Frontiers in Public Health
80. Viral loads observed under competing strain dynamics
    James A. Hay, Lee Kennedy‐Shaffer, Michael Joseph Mina · 2021 · medRxiv
81. Evolutionary history of the SARS-CoV-2 Gamma variant of concern (P.1): a perfect storm
    Yuri Yépez, Mariana Marcano-Ruiz, Rafael S Bezerra, Bibiana Fam, João PB Ximenez, Wilson A Silva Jr, María Cátira Bortolini · 2022 · Genetics and Molecular Biology
82. Vaccine-Induced Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Response and the Path to Accelerating Development (Determining a Correlate of Protection)
    Amy C Sherman, Michaël Desjardins, Lindsey Robert Baden · 2021 · Clinics in Laboratory Medicine
83. The Impact of COVID-19 Pandemic on Seafood Safety and Human Health
    Nikheel Bhojraj Rathod, Nariman El Abed, Fatih Özoğul, Joe Mac Regenstein, Charis M. Galanakis, Sulaiman Omar Aljaloud, Salam Adnan Ibrahim · 2022 · Frontiers in Microbiology
84. High infectious disease burden as a basis for the observed high frequency of asymptomatic SARS-CoV-2 infections in sub-Saharan Africa
    K. Kusi, Augustina Frimpong, F. Partey, Helena Lamptey, L. Amoah, M. Ofori · 2021 · AAS Open Research
85. Early warning and rapid public health response to prevent COVID-19 outbreaks in long-term care facilities (LTCF) by monitoring SARS-CoV-2 RNA in LTCF site-specific sewage samples and assessment of antibodies response in this population: prospective study protocol
    Bonita E. Lee, Christopher A. Sikora, Douglas Faulder, Eleanor Risling, Lorie A Little, Yuanyuan Qiu, Tiejun Gao, Ross Bulat, Stephen A. Craik, Steve E. Hrudey et al. · 2021 · BMJ Open
86. Sulfated Glycomimetic α-Helical Polypeptides for Antiviral Activity.
    Xiang Xu, Ruimin Liang, Yubin Zheng · 2023 · Biomacromolecules
87. Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs
    Enqing Tan, Erica Frew, Jeff Cooper, John Humphrey, Matthew T. G. Holden, Amanda Restell Mand, Jun Li, Shaya Anderson, Ming Bi, Julia M. Hatler et al. · 2021 · Diagnostics
88. Coronavirus: occurrence, surveillance, and persistence in wastewater
    Snehalatha Basavaraju, Jamuna Bai Aswathanarayan, Madhu B. S., Somanathan Balasubramanian · 2021 · Environmental Monitoring and Assessment
89. COVID-19 vaccines approved in the European Union: current evidence and perspectives
    Stefania Bellino · 2021 · Expert Review of Vaccines
90. Loss of Neutralizing Antibody Response to mRNA Vaccination against SARS-CoV-2 Variants: Differing Kinetics and Strong Boosting by Breakthrough Infection
    John Parker Evans, Cong Zeng, Claire Carlin, Gerard Lozanski, Linda J. Saif, Eugene M. Oltz, Richard J. Gumina, Shan‐Lu Liu · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
91. Live and let die: signaling AKTivation and UPRegulation dynamics in SARS-CoVs infection and cancer
    Mariana Suaya, Gonzalo Manuel Sanchez, Antonella Vila, Analía Amante, María Cotarelo, Mercedes García Carrillo, Matı́as Blaustein · 2022 · Cell Death and Disease
92. A comprehensive review of BBV152 vaccine development, effectiveness, safety, challenges, and prospects
    Farokh Dotiwala, Arun K. Upadhyay · 2022 · Frontiers in Immunology
93. Next‐Generation Vaccines: Nanovaccines in the Fight against SARS‐CoV‐2 Virus and beyond SARS‐CoV‐2
    Maluta Steven Mufamadi, Mpho Phehello Ngoepe, Ofentse Nobela, Nhlanhla Maluleke, Bafedile Phorah, Banele Methula, Thapelo Maseko, Dipuo Ingrid Masebe, Hazel Tumelo Mufhandu, Lebogang Katata‐Seru · 2023 · BioMed Research International
94. Bioinformatic Analysis of B- and T-cell Epitopes from SARS-CoV-2 Structural Proteins and their Potential Cross-reactivity with Emerging Variants and other Human Coronaviruses
    Diana Laura Pacheco-Olvera, Stephanie Saint Remy-Hernández, María Guadalupe García-Valeriano, Tania Rivera-Hernández, Constantino III Roberto López-Macías · 2022 · Archives of Medical Research
95. COVID-19-related research in Africa: a cross-sectional review of the International Clinical Trial Registration Platform (ICTRP)
    B. Edem, V. Williams, C. Onwuchekwa · 2021 · Trials
96. Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants
    Yuntao Zhang, Wenjie Tan, Zhiyong Lou, Baoying Huang, Weimin Zhou, Yuxiu Zhao, Jin Zhang, Hongyang Liang, Na Li, Xiujuan Zhu et al. · 2022 · Vaccines
97. De novo design and Rosetta‐based assessment of high‐affinity antibody variable regions (Fv) against the SARS‐CoV‐2 spike receptor binding domain (RBD)
    V. Boorla, Ratul Chowdhury, Ranjani Ramasubramanian, Brandon Ameglio, Rahel Frick, Jeffrey J. Gray, C. Maranas · 2022 · Proteins: Structure, Function, and Bioinformatics
98. Targeting the RBD of Omicron Variant (B.1.1.529) with Medicinal Phytocompounds to Abrogate the Binding of Spike Glycoprotein with the hACE2 Using Computational Molecular Search and Simulation Approach
    Abdulrahim Refdan Hakami · 2022 · Biology
99. Is increased mortality by multiple exposures to COVID-19 an overseen factor when aiming for herd immunity?
    Kristina Barbara Helle, Arlinda Sadiku, Girma Mesfin Zelleke, Aliou Bouba, Toheeb Babatunde Ibrahim, Henri Christian Junior Tsoungui Obama, Vincent Appiah, Gideon Akumah Ngwa, Miranda Ijang Teboh-Ewungkem, Kristan Alexander Schneider · 2021 · PLoS ONE
100. Smallpox's antiquity in doubt
     T. Newfield, A. Duggan, H. Poinar · 2022 · Journal of Roman Archaeology